Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice

K van Norren*,1,5, D Kegler1, JM Argilés2, Y Luiking1, M Gorselink3, A Laviano4, K Arts5, J Faber1, H Jansen1, EM van der Beek1 and A van Helvoort1

1Nutrition and Pharmacology Group, Division of Human Nutrition, Wageningen University, The Netherlands; 2Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Spain; 3Center for Innovative Consumer Studies, Wageningen UR, The Netherlands; 4Department of Clinical Medicine, University La Sapienza, Rome, Italy; 5Department of Food and Pharmacology, University of Wageningen, The Netherlands

Cancer cachexia is characterised by metabolic alterations leading to loss of adipose tissue and lean body mass and directly compromises physical performance and the quality of life of cancer patients. In a murine cancer cachectic model, the effects of dietary supplementation with a specific combination of high protein, leucine and fish oil on weight loss, muscle function and physical activity were investigated. Male CD2F1 mice, 6–7 weeks old, were divided into body weight-matched groups: (1) control, (2) tumour-bearing, and (3) tumour-bearing receiving experimental diets. Tumours were induced by s.c. inoculation with murine colon adenocarcinoma (C26) cells. Food intake, body mass, tumour size and 24 h-activity were monitored. Then, 20 days after tumour/vehicle inoculation, the animals were killed and muscle function was tested ex vivo. Tumour-bearing mice showed reduced carcass, muscle and fat mass compared with controls. EDL muscle performance and total daily activity were impaired in the tumour-bearing mice. Addition of single nutrients resulted in no or modest effects. However, supplementation of the diet with the all-in combination of high protein, leucine and fish oil significantly reduced loss of carcass, muscle and fat mass (loss in mass 45, 52 and 65% of TB-con, respectively (P<0.05)). Moreover, total daily activity normalised after intervention with the specific nutritional combination (50% of the reduction in activity of TB-con (P<0.05)). In conclusion, a nutritional combination of high protein, leucine and fish oil reduced cachectic symptoms and improved functional performance in cancer cachectic mice. Comparison of the nutritional combination with its individual modules revealed additive effects of the single components provided.

Keywords: muscle; wasting; nutrition; cachexia; leucine; fish oil

Cancer cachexia is one of the most debilitating aspects of cancer and has been associated with increased morbidity and mortality, reduced quality of life, impaired response to chemotherapy, increased susceptibility to chemotherapy-induced toxicity and a higher incidence of post-operative complications (Argiles, 2005). A consensus on the definition for cachexia has been reached at the 4th International Conference on Cachexia at Tampa (Consensus definition cachexia/Cachexia Conference Tampa 2007: ‘Cachexia, also known as Wasting Disease, is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass. The prominent clinical feature of cachexia is weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders). Anorexia, inflammation, insulin resistance and increased muscle protein breakdown are frequently associated with cachexia. Cachexia is distinct from starvation, age-related loss of muscle mass, primary depression, malabsorption and hyperthyroidism and is associated with increased morbidity’.) (Evans et al, 2008). Cancer cachexia is characterised by involuntary weight loss with a depletion of not only fat mass, but also lean body mass due to muscle wasting. Symptoms besides weight loss are debilitation, weakness, oedema, impaired immune response, and a decline of motor and mental functions (Argiles, 2005). Approximately 45% of cancer patients lose more than 10% of their pre-diagnostic weight (Argiles, 2005). The tumour can induce changes in protein metabolism, resembling those found in infection or injury (Argiles, 2005). These changes are characterised by a net protein breakdown and an increased oxidation of branched-chain amino acids (BCAAs), especially in muscle, to support energy supply (e.g., gluconeogenesis from amino acid carbon skeletons) and to provide amino acids for the synthesis of acute phase proteins ((Baracos and Mackenzie, 2006; Choudry et al, 2006) for reviews). The breakdown of the host protein is partly stimulated by inflammatory mediators (e.g., TNFα, IL-6) produced not only by the host, but also by the tumour (Argiles, 2005).
We hypothesise that nutritional support in cancer patients should aim for a direct counteraction of the net body protein breakdown, rather than for a mere increase in caloric intake. To establish a net positive protein balance, protein supplementation should be combined with specific components modifying and mitigating both the catabolic and anabolic signals.

Fish oil derived N-3 polyunsaturated fatty acids (PUFAs) (Colomer et al. 2007) may have anti-catabolic effects through a reduction of the inflammatory state. The vast majority of the clinical trials in which fish oil derived n-3 PUFAs were tested report an increase (Wigmore et al. 1996, 2000; Barber et al. 1999, 2001; Jatoi et al, 2004) or maintenance (Burns et al. 1999, 2004; Fearon et al. 2003) of body weight (BW), whereas in two other clinical trials no effect on the loss of BW was found (Gogos et al., 1998; Bruera et al., 2003). In the latter, however, the supplementation period was only 2 weeks (Bruera et al., 2003) and/or only a small number of patients was included (Gogos et al., 1998). In a clinical trial in pancreatic cancer patients, in which a fish oil-enriched product was tested against an isocaloric/isonitrogenous placebo, no differences between groups were found on either LBM or physical activity. However, when compared with baseline values, total energy expenditure, resting energy expenditure and physical activity level increased significantly in those randomised to the n-3 enriched supplement (Moses et al., 2004). Other studies on supplementation with EPA or fish oil, specifically in cancer patients, showed a net lean tissue mass gain (Fearon et al., 2003), an increase in total resting energy expenditure and physical activity, a decreased need for total parenteral nutrition (TPN) (Kemler et al., 1996) and an improved quality of life (Fearon et al., 2003; Burns et al., 2004). One study suggested improved survival (Gogos et al., 1998).

Protein synthesis cannot occur without the presence of the building units, the amino acids. In fact, a high supply of essential amino acids has been described to be essential for increasing protein synthesis (Rooyackers and Nair, 1997), indicating that not only the quantity, but also the quality of the amino acid supply is vital. Therefore, the protein fraction supplemented has to be rich in essential amino acids.

BCAAs and especially leucine are known to control skeletal muscle protein metabolism (Kobayashi et al., 2006) by stimulating protein synthesis and inhibiting protein breakdown. Prospective caloric- and nitrogen-controlled trials of BCAA supplementation through TPN in septic patients indeed resulted in an improvement of pre-albumin levels and a decreased overall mortality (Jimenez Jimenez et al., 1991; Garcia-de-Lorenzo et al., 1997). Anthony and co-workers showed in various rat models that leucine enhances protein synthesis in skeletal muscle through both insulin-dependent and -independent mechanisms (Anthony et al., 2002a,b). In tumour-bearing rats a diet supplemented with 3% leucine has been reported to reduce loss of lean body mass, gastrocnemius muscle mass and myosin content, when compared to an isonitrogenous and isocaloric control diet (Gomes-Marcondes et al., 2003). These data are supported by the observation that leucine increased protein synthesis in pregnant tumour-bearing rats, possibly resulting from changes in the ubiquitin–proteasome system (Ventrutti et al., 2004). In humans, leucine supplementation resulted in an improved muscle protein synthesis in young (Koopman et al., 2005) and elderly volunteers (Katsanos et al., 2006; Koopman et al., 2006; Rieu et al., 2006). There are two clinical trials in cancer patients that studied oral BCAA supplementation after surgical removal of the tumour. These studies reported a shorter hospital stay, a better performance status at 3 months and an increased body mass at 1 year following surgery (Surgery, 1997; Meng et al., 1999). BCAs have also been supplemented in the presence of the tumour: patients undergoing chemotherapy received oral BCAA supplementation up to 1 year after the start of chemotherapy, resulting in a lower overall morbidity, an improved nutritional status and a better quality of life (Poon et al., 2004).

We hypothesise that nutritional support in cancer patients is most effective if aimed simultaneously for a variety of parameters involved in cachexia. Therefore, we studied, in a cancer cachectic murine model, the effect of a combined nutritional supplementation high in protein, rich in leucine and EAA and fish oil compared with single-compound supplementation, on cancer-induced weight loss. Next, also the effects on clinically relevant functional readouts, such as muscle function and physical activity were investigated. To this end the colon 26 adenocarcinoma bearing the cachectic mouse model was used, which has repeatedly shown the loss of muscle mass and muscle function without significant effects on food intake (Tanaka et al., 1990; Díllee et al., 2002; Gorselink et al., 2006), which makes it a suitable model to study the effect of specific nutritional ingredients on cancer cachexia.

**MATERIALS AND METHODS**

**Animals**

Male C57BL/6J mice at 6–7 weeks, (BALB/c × DBA/2, Harlan/Charles River, the Netherlands) were individually housed in a climate-controlled room (12:12 dark–light cycle with a constant room temperature of 21 ± 1°C). After acclimatisation for 1 week mice were divided into weight-matched groups: (1) control receiving control chow, (2) tumour-bearing receiving control chow, and (3) tumour-bearing receiving experimental diets. Data shown are derived from the combination of several experimental runs with identical animal characteristics and experimental procedures (unless stated otherwise) and differ only in the experimental diets used. All experimental procedures were approved by the Animal Ethical Committee (DEC consult, Bilthoven, The Netherlands) and complied with the principles of good laboratory animal care.

**Experimental diets (categories A and B experiments)**

Experiments are divided in: (A) experiments designed to test the effect of single or combined nutritional components (addition of high protein (hpr), leucine (leu), fish oil (fo)), added to the background diet (AIN93-M) and supplied as pellets; (B) experiments designed to test the effect of a complex nutritional combination that resembles the composition of the new Fortifed (Nutricia Advanced Medical Nutrition).

The AIN93-M control diet in the category A experiments contained per kg feed: 126 g protein (100% casein), 727 g carbohydrates and 40 g fat (100% soy oil) (Research Diet Services, Wijk bij Duurstede, the Netherlands). Experimental diets in this category were adjusted to control diets by partly replacing the carbohydrates and/or soy oil by protein and leucine (151 g casein/kg and 16 g leucine/kg feed; TB + hpr + leu), high protein and fish oil (151 g casein/kg and 22 g fish oil/kg feed; TB + fo + hpr), or high protein and leucine and fish oil (151 g casein/kg, 16 g leucine/kg and 22 g fish oil/kg food; TB + fo + hpr + leu). The 22 g of fish oil contained 6.9 g EPA and 3.1 g DHA in a ratio of 2.2:1. In summary, in experiment A the following diets and interventions were compared: (1) no tumour, AIN93-M fed (Con); (2) tumour-inoculated AIN93-M fed (TB-con); (3) tumour-inoculated fed AIN93-M with additional protein and leucine (TB + hpr + leu); (4) tumour-inoculated fed AIN93-M with additional fish oil (TB + fo); (5) tumour-inoculated fed AIN93-M with additional fish oil and protein (TB + fo + hpr); (6) tumour-inoculated fed AIN93-M with additional fish oil, high protein and leucine (TB + fo + hpr + leu).

In the category B experiment, the control diet was a more humanised diet, isocaloric and isonitrogenous to the control diet in the A category of experiments, and contained per kg feed 126 g protein (casein), 53 g fat (corn oil), and 699 g carbohydrates. The isocaloric experimental diet (further referred to as Specific Nutritional Composition; SNC) contained per kg feed: 210 g protein (189 g intact protein of which 68% casein and 32% whey...
and 21 g free leucine), 53 g fat (20.1 g corn oil, 10.2 g canola oil, and 22.2 g fish oil (providing 6.9 g EPA and 3.1 g DHA)), 561 g carbohydrates, 18 g galacto-oligosaccharides and 2 g fructo-oligosaccharides. In experiment B, diets were supplied as dough for product technical reasons.

**Tumour model**

Murine C-26 adenocarcinoma cells were cultured in vitro with RPMI-1640 supplemented with 5% fetal calf serum and 1% penicillin–streptomycin (Tanaka et al., 1990). Tumour cells were trypsinised in a sub-confluent state and, after washing, suspended in Hanks’ balanced salt solution (HBSS) at a concentration of 2.5 × 10⁶ cells ml⁻¹. Under general anaesthesia (isoflurane/N₂O/O₂), tumour cells (5 × 10⁵ cells in 0.2 ml) were inoculated subcutaneously into the right inguinal flank of the mice. Control (G) animals received a sham injection with 0.2 ml HBSS.

**Experimental protocol**

Following inoculation of tumour cells or HBSS, body mass, food intake and tumour size (length and width) were measured three times a week. Only in the category B experiment, daily activity in the home cage was monitored. In all experiments, animals were anaesthetised and weighed at day 20 after tumour inoculation. Skeletal muscles (e.g., m. Tibialis Anterior (mTA), m. Gastrocnemius (mG), m. Extensor Digitorum Longus (mEDL) and M Soleus (mS)), the tumour, spleen, kidneys, liver, epididymal fat, thymus, lungs and heart were dissected and weighed. Carcass mass was calculated by subtracting tumour mass from body mass. In addition, muscle function was tested ex vivo in the category B experiment.

**Assessment of daily activity**

Physical activity was monitored continuously (24 h) during the 20-day study period starting at day 2, using activity sensors (dual technology detector DUO 240, Visonic; adapted by R Visser, NIN, Amsterdam, The Netherlands) that translated individual changes in the infrared pattern caused by movements of the animals into arbitrary activity counts. Sensors were mounted above the home cages and were connected through input ports and interface to a computer equipped with MED-PC IV software for data collection (MED associates, St Albans, VT, USA). Activity was expressed in counts per hour (both for the total 24-h period, the dark period (active period) and the light period (inactive period)). Activity was calculated for each mouse separately and was expressed relative to its own total activity on day 2, to correct for differences in the individual sensitivity of sensors. The activities of two subsequent days were averaged, to dampen the day to day variability. To determine changes in the activity pattern throughout the experiment, hourly and daily – light activity were expressed as percentage of total daily activity and translated into an actogram.

**Assessment of muscular functionality**

Contractile characteristics of the right EDL muscle were assessed ex vivo, as described previously (Gorselink et al., 2006). Briefly, muscles were allowed to stabilise in the organ bath for 30 min, after which optimal stimulation current and strength were determined. Then force-frequency characteristics (10–167 Hz, 250 ms) were determined and after replenishing the organ buffer and a resting period of 5 min, muscles were subjected to an exercise protocol (83 Hz, 250 ms every 1000 ms). This protocol represents a moderate load, comparable with normal daily activity. At the frequency used, complete tetanus of the muscle is reached. Isometric force signals of the force–frequency curve were analysed for maximal and total force and for maximal contraction and relaxation velocity.

**Statistics**

All data are expressed as means ± s.e.m. Statistical analyses were performed using SPSS 15.0 (SPSS Benelux, Gorinchem, the Netherlands). In experiment A different batches of animals were used, therefore, for all parameters it was defined that combination of data was allowed if no interaction between groups and experiments were present. Body composition data, tumour and organ masses on day 20 were compared between groups with analysis of variance (ANOVA) and post hoc LSD. Differences were considered significant at a P-value below z/k; in which z = 10% and k = amount of comparisons. For experiment A the P-value had to be below 0.02; for experiment B the P-value had to be below 0.05. Data on food intake, body weight, daily activity, and muscle function that were monitored during the 20 days after inoculation were analysed by repeated measures ANOVA. To further discriminate the differences between groups, the differences or deltas from the first measurement in the range were calculated. These deltas were compared between groups using ANOVA, with post hoc LSD for pairwise comparison between groups. For skeletal muscle function, data of first measurement at day 20 were not similar between groups, therefore further discrimination was performed in a per point analysis ANOVA. Differences were considered significant at a two-tailed P<0.05.

**RESULTS**

**Effects of single vs combined nutritional components on different parameters of cachexia**

Compared with control mice (Con), carcass and body weight were significantly lower in tumour-bearing control mice (TB-con) on day 20 after tumour inoculation (Table 1A). For all parameters measured there was no group times experiment interaction. The loss of body weight in TB-con mice was derived from both loss of muscle mass and fat mass (e.g., epididymal fat) (Figure 1A and B). No differences in food intake were present between groups for complete curves. When analysed separately per day, at day 20, Con was significantly different from TB-con. None of the tumour-bearing groups were significantly different from each other (Table 1B). Addition of extra protein and leucine (TB + hpr + leu) or fish oil (TB + fo) did not change body weight compared with TB-con (Table 1A). However, addition of fish oil to extra protein (TB + fo + hpr) or fish oil to extra protein and leucine (TB + fo + hpr + leu), resulted in a significant higher fat mass compared with TB-con (Figure 1B). Only the supplementation of the diet with the all-in combination of high protein, leucine and fish oil (TB + fo + hpr + leu) resulted in a significant improvement of body and carcass weight (Table 1A), and of muscle (mTA) and fat (epididymal) mass, compared with TB-con mice (Figure 1). Additive effects of the combination of leucine and high protein were found for muscle mass of the mTA in the presence of fish oil. Addition of each component increased muscle mass stepwise (Figure 1A).

**Effect of a specific nutritional combination on parameters of cachexia**

Body and carcass weight were significantly lower in tumour-bearing mice (TB-CON) compared with control mice (CON) on day 20 (Table 2A). The difference in body weight change already being significant at day 15 after tumour inoculation (Table 2C). Again, a significant lower fat mass (epididymal fat) and muscle mass was observed in the TB-CON mice (Table 2B). Food intake
Nutritional supplementation resulting in increased carcass weight partly compensated the weight loss. For experiment B the data for organ masses (in percentage of control (CON) ± s.e.m.) were: kidney: TB-CON: 81% ± 2; TB-SNC: 91% ± 2, liver TB-CON: 88% ± 2; TB-SNC: 92% ± 3, thymus TB-CON: 46% ± 4; TB-SNC: 55% ± 4, heart TB-CON: 86% ± 2; TB-SNC: 88% ± 2, and lung: TB-CON: 98% ± 2; TB-SNC: 103% ± 3. Tumour mass was not increased by any of the nutritional supplementations (Tables 1 and 2).

**Ex vivo muscle function (category B experiment)**

Force–frequency characteristics (10–167 Hz, 250 ms) were determined ex vivo in mEDL. Maximal force, maximal contraction velocity and maximal relaxation velocity were significantly different in TB-CON when compared with CON and TB-SNC (Figure 2A, B and C). When these parameters were corrected for muscle mass, overall curve positions were maintained. Significant differences, however, remained only between CON and TB-CON. To further investigate muscle mass-independent changes in muscle function the time needed for a contraction (CT90) was determined. CT90 was defined as the time needed to go from 10 to 90% of maximal contraction force, at frequencies at which tetanus was obtained (83 and 100 Hz). These data suggest that at frequencies (83–100 Hz) relevant for efficient physical performance (tetanus present), besides muscle mass-dependent changes, also muscle mass-independent changes had occurred that were corrected by specific nutritional intervention. Therefore, an exercise protocol of 100 repeated pulses was applied at 83 Hz. Again, CON and TB-SNC were significantly different from TB-CON during the whole exercise protocol for maximal contraction force (Figure 3A) and maximal contraction velocity (Figure 3C). When maximal contraction force was corrected for muscle mass (Figure 3B) curve positions remained, with only significant differences between CON and TB-CON. Maximal contraction velocity of the TB-SNC group; however, was still significantly different from TB-CON when corrected for muscle mass in the first repeats of the exercise (<10 repeats) (Figure 3D).

---

**Table 1** Effects of single or combined nutritional components on body composition, and food intake (experiment A)

| Treatment       | N  | Carcass weight | P  | Body weight | P  | Tumour weight | P  |
|-----------------|----|----------------|----|-------------|----|--------------|----|
| Con             | 40 | 24.4 ± 0.3     | 0.000* | 24.4 ± 0.3 | 0.001* | 0.0 ± 0.0 | 0.0000* |
| TB-con          | 40 | 20.7 ± 0.4     | —   | 22.8 ± 0.4  | —   | 2.2 ± 0.1   | —   |
| TB-hpr+leu      | 10 | 20.0 ± 0.6     | 0.807 | 21.8 ± 0.6 | 0.992 | 1.8 ± 0.1 | 0.1472 |
| TB+fo           | 10 | 20.9 ± 0.8     | 0.226 | 23.0 ± 0.8 | 0.238 | 2.1 ± 0.1 | 0.6854 |
| TB+fo+hpr       | 10 | 22.2 ± 0.6     | 0.034 | 24.2 ± 0.7 | 0.038 | 2.0 ± 0.1 | 0.5023 |
| TB+fo+hpr+leu   | 22 | 22.7 ± 0.6     | 0.010* | 24.4 ± 0.5 | 0.019* | 1.7 ± 0.1 | 0.0659 |

**Table 2A** Carcass, tumour and fat masses at section (grams at day 20)

| Treatment       | N  | Carcass weight | P  | Tumour weight | P  |
|-----------------|----|----------------|----|--------------|----|
| Con             | 40 | 24.4 ± 0.3     | 0.000* | 0.0 ± 0.0 | 0.0000* |
| TB-con          | 40 | 20.7 ± 0.4     | —   | 2.2 ± 0.1   | —   |
| TB-hpr+leu      | 10 | 20.0 ± 0.6     | 0.807 | 1.8 ± 0.1 | 0.1472 |
| TB+fo           | 10 | 20.9 ± 0.8     | 0.226 | 2.1 ± 0.1 | 0.6854 |
| TB+fo+hpr       | 10 | 22.2 ± 0.6     | 0.034 | 2.0 ± 0.1 | 0.5023 |
| TB+fo+hpr+leu   | 22 | 22.7 ± 0.6     | 0.010* | 1.7 ± 0.1 | 0.0659 |

**Table 2B** Food intake (gram per day)

| Treatment       | N  | Day 1 | Day 7 | Day 14 | Day 17 | Day 19 | Day 20 |
|-----------------|----|-------|-------|--------|--------|--------|--------|
| Con             | 40 | 4.5   | 3.8   | 4.0    | 3.8    | 3.7    | 3.6    |
| TB-con          | 40 | 4.2   | 3.9   | 4.0    | 3.1    | 3.7    | 3.5    | 2.9    |
| TB-hpr+leu      | 10 | 4.7   | 3.9   | 4.1    | 3.1    | 3.7    | 3.1    | 2.3    |
| TB+fo           | 10 | 5.4   | 3.9   | 3.9    | 3.7    | 3.3    | 2.6    |
| TB+fo+hpr       | 10 | 4.4   | 3.9   | 3.9    | 3.7    | 3.3    | 3.4    |
| TB+fo+hpr+leu   | 22 | 4.4   | 3.9   | 3.9    | 3.7    | 3.3    | 3.4    | 3.0    |

---

**Figure 1** Differences in muscle and fat mass at day 20 after interventions with single or combined nutritional components (Experiment A). (A) muscle Tibialis Anterior mass and (B) Epididymal fat mass. Con = mice receiving control diet A (AIN93), TB-con = tumour-bearing mice receiving control diet A (AIN93), hpr = high protein, leu = leucine, fo = fish oil. Data are means ± s.e.m.; *significantly different from TB-con (P < 0.02; k = 5, α = 10%) (For more details about statistics, see the Materials and Methods section).
**Table 2** Effects of the specific nutritional combination (SNC) on cachexia parameters (experiment B)

(A) Body, tumour and carcass weight at section (g at day 20)

| Treatment | N   | BW         | Delta BW | TW   | CW         | Delta CW |
|-----------|-----|------------|----------|------|------------|----------|
| CON       | 10  | 28.0 ± 0.7*| 5.3 ± 0.5*| 0.0 ± 0.0*| 28.0 ± 0.7*| 5.3 ± 0.5*|
| TB-CON    | 17  | 20.8 ± 0.5 | -0.7 ± 0.4| 2.1 ± 0.1 | 18.7 ± 0.4 | -2.8 ± 0.4|
| TB-SNC    | 18  | 23.1 ± 0.6*| 0.9 ± 0.6*| 1.7 ± 0.1*| 21.4 ± 0.6*| -0.7 ± 0.7*|

(B) Organ weights at section (mg at day 20)

| Treatment | N   | Organ mass | mTA    | mG      | mEDL | mS       |
|-----------|-----|------------|--------|---------|------|----------|
| CON       | 10  | 443 ± 37*  | 44.5 ± 1.3* | 141 ± 4* | 9.2 ± 1.1 | 67.1 ± 0.5*|
| TB-CON    | 17  | 87 ± 1.8   | 33.4 ± 0.9 | 108 ± 2 | 7.8 ± 0.2 | 53.7 ± 0.2*|
| TB-SNC    | 18  | 189 ± 20*  | 38.1 ± 0.9*| 118 ± 3* | 8.3 ± 0.5 | 5.7 ± 0.2*|

(C) Change in BW in time

| Treatment | N | 0     | 6     | 10   | 15   | 20   |
|-----------|---|-------|-------|------|------|------|
| CON       | 10| 1.0 ± 0.3 | 3.6 ± 0.4 | 4.3 ± 0.7 | 5.5 ± 1.0* | 6.3 ± 1.4* |
| TB-CON    | 17| 0.6 ± 0.3 | 2.7 ± 0.3 | 3.3 ± 0.3 | 3.7 ± 0.4 | -0.1 ± 0.5 |
| TB-SNC    | 18| 0.9 ± 0.2 | 3.4 ± 0.3 | 4.4 ± 0.4 | 4.6 ± 0.4 | 1.8 ± 0.6* |

(D) Food intake in time

| Treatment | N | 8 | 13 | 17 | 19 |
|-----------|---|---|----|----|----|
| CON       | 10| 4.4 ± 0.2 | 4.3 ± 0.2 | 4.4 ± 0.3 | 3.5 ± 0.6 |
| TB-CON    | 17| 4.0 ± 0.2 | 4.1 ± 0.1 | 3.7 ± 0.3 | 3.5 ± 0.5 |
| TB-SNC    | 18| 4.2 ± 0.1 | 4.5 ± 0.2 | 4.8 ± 0.3 | 4.4 ± 0.4 |

Table 3 Effects of the specific nutritional combination (SNC) on cancer cachexia-induced organ mass changes (experiment B)

| Treatment | N   | Kidney | Liver | Thymus | Lung  |
|-----------|-----|--------|-------|--------|-------|
| CON       | 10  | 422 ± 10.9 | 1196.8 ± 123.3 | 40.3 ± 10.9 | 0.0000*|
| TB-CON    | 17  | 342 ± 8.0  | 1050.1 ± 92.3  | 185 ± 6.9  | 0.01749|
| TB-SNC    | 18  | 385 ± 9.3  | 1101.1 ± 125.5 | 22.3 ± 7.3 | 0.715 |

| Treatment | N   | Heart | Lung  |
|-----------|-----|-------|-------|
| CON       | 10  | 150.9 ± 3.1 | 161.9 ± 4.4  | 0.715  |
| TB-CON    | 17  | 129.4 ± 2.7  | 159.3 ± 3.7  | 0.196  |
| TB-SNC    | 18  | 133.6 ± 3.1  | 1670 ± 4.8   | 0.196  |

CON = mice receiving control diet B, TB-CON = tumour-bearing mice receiving control diet B, TB-SNC = tumour-bearing mice receiving the specific nutritional combination. BW = body weight; CW = carcass weight; delta BW = BW day 20 minus BW day 0, delta CW = CW day 20 minus CW day 0, TW = tumour weight, mTA = muscle Tibialis Anterior, mG = muscle Gastrocnemius, mEDL = muscle Extensor Digitorum Longus, mS = muscle Soleus. Data as mean ± s.e.m.; *significantly different from TB-CON (P < 0.05, k = 2, α = 10%). (For more details about statistics, see the Materials and Methods section).

Physical activity (category B experiment)

Total daily activity showed a significant interaction between time and group (P < 0.01; RM-ANOVA) over the total period (2–19 days). Activity levels in TB-CON mice were significantly lower than in control mice on days 10–11 (P < 0.05), and from day 16 onwards (P < 0.01). The TB-SNC animals did not differ significantly from the control animals in their total activity throughout the experiment, whereas their activity was significantly higher at days 18–19 compared with TB-CON mice (P < 0.05) (Figure 4A). These differences in total activity resulted from significant changes during their active period (i.e., dark period) (Figure 4B). Throughout the dark period, TB-CON mice were significantly less active than controls on days 16–17 and 18–19 (P < 0.01), resulting in a drastic decrease in overall activity in the TB-CON mice. The TB-SNC mice were less active than control mice during the dark on day 18–19 (P < 0.05), but more active than TB-CON mice on those days (P < 0.05).

Besides a reduction in daily activity level of TB-CON mice, a clear shift in daily activity pattern was observed, that is, from dark to light, both in tumour-bearing controls and in TB-SNC animals on days 18–19 (Figure 4C). To focus on possible shifts in daily activity pattern, hourly activity pattern during the day was expressed as a percentage of the total (100%) daily activity on...
Figure 2  The effect of the specific nutritional combination on skeletal muscle function: force frequency curve (ex vivo experiment B). CON = mice receiving control diet B, TB-CON = tumour-bearing mice receiving control diet B, TB-SNC = tumour-bearing mice receiving the specific nutritional combination. Data are means ± s.e.m.; data were significantly different from TB-CON when \( P < 0.05 \) (\( k = 2, \alpha = 10\% \)). (A) Maximal contraction force (complete curves significantly different from each other \( P < 0.01 \)). (B) Maximal contraction velocity (complete curves significantly different from each other \( P < 0.01 \)). (C) Maximal relaxation velocity (complete curves significantly different from each other \( P < 0.01 \)). (D) CT90: time needed for contraction from 10 to 90% of maximal force (CON significantly different from TB-CON for range 83–176 Hz; TB-SNC significantly different from TB-CON for range 83–100 Hz).

Figure 3  The effect of the specific nutritional combination on skeletal muscle function during exercise (ex vivo experiment B). CON = mice receiving control diet B, TB-CON = tumour-bearing mice receiving control diet B, TB-SNC = tumour-bearing mice receiving the specific nutritional combination. Data as means ± s.e.m.; data were significantly different from TB-CON when \( P < 0.05 \), \( k = 2, \alpha = 10\% \). (A) Maximal contraction force (both curves are significantly different from TB-CON till repeat 70). (B) Maximal contraction force corrected for muscle mass (CON is significantly different from TB-CON for repeats 30–50; TB-SNC not significantly different from TB-CON). (C) Maximal contraction velocity (both curves significantly different from TB-CON till repeat 70). (D) Maximal contraction velocity corrected for muscle mass (CON significantly different from TB-CON for the first 30 repeats (except for repeat 5 \( P = 0.06 \)); TB-SNC significantly different from TB-CON for the first 10 repeats).
that specific day (Figure 4D) (i.e., not referring to day 2 and not corrected for the graduate decline in activity for the tumour-bearing groups). At baseline (days 2–3) all groups showed comparable day/night rhythms. Animals were active during the dark and had an inactive period during the light. A relative shift towards increased activity during the light period is observed in the TB-CON group from day 16, which occurs less or delayed in the TB-SNC group.

**DISCUSSION**

In this study, the effect of a nutritional supplementation with single vs multiple components on body composition in the murine C26 carcinoma model was investigated. In contrast to supplementation of the single ingredients, the combination demonstrated a significant effect on the body composition. In addition, the specific nutritional combination also improved muscle function. Moreover, activity patterns as well as overall daily activity improved, probably as a consequence of improved body composition and muscle function. This clearly supports the added value of a multi target approach, in which catabolism (both protein and fat) is targeted through a reduction of inflammation through the addition of fish oil; whereas anabolism is specifically targeted by protein synthesis through the supplementation of high protein and leucine. The effects on body composition and performance are highly relevant to the clinical situation, because muscle function and daily activity are important contributors to the quality of life of the cancer patient (Morrow et al., 2002). Moreover, from a retrospective study in 1555 patients with gastrointestinal carcinomas it was concluded that patients with weight loss had a poorer outcome from treatment than patients without weight loss. This difference contributed to the fact that the patients with weight loss received significantly less chemotherapy and experienced more toxicity from the treatment (Andreyev et al., 1998). These findings indicate that maintenance of body composition may beneficially contribute to compliance of the patient to the therapy.

The data focus on the specific needs of the cancer patient and the possible role for nutrition in improving or preventing cachexia characteristics. The data show the effects of different isocaloric nutritional interventions with single ingredients or combinations in the C26 murine model of cancer-induced cachexia. There were no significant differences on food intake between groups on complete curves nor on analysis per day up to day 19. These data confirm earlier findings that for cachexia, validated C26 adenocarcinoma mouse model can be used as a cachectic non-anorectic model (Tanaka et al., 1990; Diffee et al., 2002; Gorselink et al., 2006). The observation, however, that in experiment A, food intake of Con is significantly higher than that of TB mice on day 20 specifically indicates that if tumour growth would continue for a few days more, the tumour-bearing animals would likely become anorectic. The differences in cachectic parameters between control and tumour-bearing mice 20 days after tumour inoculation, were comparable in magnitude to those described in other studies also using the C26 adenocarcinoma mouse model (Lazarus et al., 1996; Matsumoto et al., 1999; Samuels et al., 2000; Fujimoto-Ouchi et al., 2006; Gorselink et al., 2006).

None of the single components had direct effects. Only the combination of fish oil and high protein increased fat mass. Fat mass has been suggested to be important in survival of the patient (Kalantar-Zadeh et al., 2007) whereas muscle mass has been implicated to contribute specifically to the quality of life of the patient (Muscaritoli et al., 2004). The data on mTA muscle mass show that at the tested concentration the combination of all components, that is, fish oil, high protein and leucine were needed for a significant effect on muscle mass (Figure 1). Moreover, the results are in line with the hypothesis that next to an increase in anabolic responses, protein catabolism has to be decreased by reduction of inflammation to reach a positive effect on muscle protein mass in a cancer cachectic state. There is growing support
that the inflammatory response to a tumour attributes considerably to the progression towards cachexia. It has also been suggested that the increase in catabolic vs anabolic processes contributes to the failure to accumulate lean body mass even when nutritional intake is normal (Argiles, 2005). Clinical data from different cachetic patient groups (Wigmore et al, 1996, 2000; Barber et al, 1999, 2001; Jatoi et al, 2004) suggest that fish oil might reduce catabolism and weight loss. Fish oil probably not only attenuates the tumour-induced inflammatory response, but also normalises the insulin resistance present in the cachectic state (Wigmore et al, 1996, 2000; Barber et al, 1999, 2001; Jatoi et al, 2004). Prolongation of survival has been reported in a mixed group of advanced cancer patients supplemented with n-3 fatty acids and vitamin E (Giovannini et al, 1998) without any effect of single nutrients or their combination on food intake in the present study. Clinical data indicate that BCAA supplementation reduces the incidence of anorexia in cancer and malnourished patients and in patients with liver cirrhosis (Cangiano et al, 1996; Hiroshige et al, 2001; Marchesini et al, 2003; Laviano et al, 2005, 2006; Biolo et al, 2006). In a placebo-controlled multi-center trial in cirrhotic patients (n = 174), 1 year supplementation with BCAA resulted in a decreased prevalence of anorexia from 52 to 25%, whereas anorexia prevalence remained unchanged in the control group (Marchesini et al, 2003). The incidence of anorexia also decreased in the BCAA supplemented group, whereas it did not change in the placebo group in a study in cachectic cancer patients supplemented with 14.4 g/day BCAA (7.1 g leucine) (Cangiano et al, 1996). Moreover, caloric intake in the BCAA group increased. Cota et al (2006) found contradictory results in vivo and reported an anorectic effect of Leucine after central administration in healthy rats. Several explanations were given by Laviano et al (2006) for this discrepancy supported by results from clinical trials. First, Cota et al (2006) used healthy rats of normal weights, whereas Laviano et al (2006) performed their study in anorectic weight-losing cancer patients, aiming to stimulate muscle weight gain in these patients. Second, leucine may exert a different effect when supplemented balanced with other amino acids through the oral route compared with injection directly into the central nervous system. The fact that our data in the C26 mice model revealed no effect of leucine supplementation on food intake may be related to the absence of anorexia in our cachectic model setup.

Combination supplementation induced a loss of muscle function, as reported previously (Gorselink et al, 2006). A large part of the reduction of muscle function was explained by a reduction in muscle mass. These findings are in accordance with clinical data. Gogos et al (1998) reported a significantly higher Karnofsky performance status in malnourished patients supplemented for 40 days with 18 g of n-3 PUFA (3 g EPA and 2 g DHA) compared with placebo. These data suggest that improvement of physical activity may occur even before a significant weight gain is achieved. This may indicate that for maintaining normal life activities, preventive treatment to reduce muscle wasting is recommended. In our experimental setup, all tumour-induced muscle mass-dependent decreases in muscle function could be significantly restored by supplementation with the specific nutritional combination. These data are supported by clinical trial data of Barber et al (2001) reporting an improved functional performance after 3 and 7 weeks of supplementation with 2.2 g EPA + 0.96 g DHA in unresectable pancreatic cancer patients. The improved physical performance coincided with increased BW and appetite. Next to muscle mass-dependent changes in muscle function, as described by Weber et al (2008), also muscle mass-independent loss of function is suggested by presented data (Figures 2D and 3D). A tumour-related, muscle mass-independent decrease in muscle function has not been described before. Weber et al (2008) described in humans that cachexia is associated with a loss of muscle volume, but not of functionality. It might be that the technique used in this study is more accurate because muscles can be weighed instead of being measured in fat-free mass.
estimated, which might result in less variation in the results. Because the largest part of function loss is in muscle mass dependent, the muscle mass independent changes might get lost in the noise of variation of the data. This compromised muscle function became especially manifest in the maximal contraction velocity after exercise of moderate strength (Figure 3C). The muscle mass-independent decrease in muscle function could also be partly restored by supplementation with the specific nutritional combination (TB-SNC). These results indicate that the nutritional combination restores both muscle mass-dependent and muscle mass-independent decreases in muscle function. 

Asthenia, resulting from cancer cachexia, leads to a reduced daily activity. Indeed, in the presence of a tumour, daily activity levels of mice decreased over time which is in line with clinical reports of cancer patients (Mormont and Levi, 1997; Mormont et al, 2000). It is not clear what mechanism induces the reduction in activity in cachectic cancer patients. Reduced muscle mass and decreased muscle force may contribute to the deterioration in activity. In addition, the tumour-induced inflammatory response might further reduce the daily activity. Physical activity is a major determinant of quality of life (Moses et al, 2004). The complete nutritional combination tested maintained activity compared with TB-CON mice. This effect may be directly related to the better maintained physical performance (improved muscle mass and function). The influence of the nutritional combination on other factors involved in physical performance, however, would need further examination.

Chevalier et al (2003) reported that patients with advanced colorectal cancer showed less contrast between day time and night time activity (nocturnal sleep). Individual activity patterns have even been suggested to be predictive of the patients’ survival, tumour response and quality of life (Mormont and Levi, 1997; Mormont et al, 2000). The possibility of a tumour-induced disturbance in diurnal activity patterns is supported by our data, indicating a tumour-related shift in activity from the dark to the light period. The specific nutritional combination tested shows a clear trend to reduce this effect. Normal sleep patterns are critically dependent on the circadian release of melatonin from the pineal gland. DHA-enriched formulas have been reported to normalise melatonin secretion in (n-3)-deficient rats (Zaouali-Ajina et al, 1999), this might also be an explanation for the results obtained in our experiments.

Further studies in patients are needed to confirm the anti-cachectic properties of a nutritional supplement containing at least leucine-enriched high protein and fish oil. Also the mechanistic effects of the nutritional combination on inflammatory processes warrant further research. When anorexia is present in this patient group, the use of a high caloric supplement seems valid. In such a setup, the effect of BCAAs in the nutritional combination on both anorexia and cachectic parameters could be evaluated. Moreover, based on the results from this study it is clear that more attention should be paid to prevention of cachexia to maintain quality of life for the patient.

In conclusion, this specific nutritional combination of high protein, leucine and fish oil improved the cachectic outcome of mice inoculated with the C26 adenocarcinoma cell line. The carcass, fat and muscle mass increased and the muscle function and daily activity improved when compared with tumour-bearing mice on the control diet. These data show that single ingredient interventions have limited value, and support the need for a balanced combination of different ingredients to enable a multi-targeted intervention to achieve beneficial effects in the complex conditions of cancer cachexia, as reflected in changes of body composition, muscle functionality and daily activity. The findings are clinically highly relevant, because muscle function and daily activity contribute to a great extent to the quality of life of the cancer patient (Morrow et al, 2002). In addition, an improved condition of a patient, as reflected in body composition and physical performance, contribute to compliance of the patient to the anti-cancer therapy (Andreyev et al, 1998).

ACKNOWLEDGEMENTS

We thank Martin Balvers and Mieke Aarts for their technical assistance and Dr Rob Verdooren for his support concerning the statistical data analysis. We also thank Dona McCarthy for the kind gift of the C26 cell line.

REFERENCES

Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34: 503 – 509

Anthony JC, Lang CH, Crozier SJ, Anthony TG, MacLean DA, Kimball SR, Jefferson LS (2002a) Contribution of insulin to the translational control of protein synthesis in skeletal muscle by leucine. Am J Physiol Endocrinol Metab 282: E1092 – E1101

Anthony JC, Reiter AK, Anthony TG, Crozier SJ, Lang CH, MacLean DA, Kimball SR, Jefferson LS (2002b) Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E-BP1 or S6K1 phosphorylation. Diabetes 51: 928 – 936

Argiles JM (2005) Cancer-associated malnutrition. Eur J Oncol Nurs 9: S39 – S50

Baracos VE, Mackenzie ML (2006) Investigations of branched-chain amino acids and their metabolites in animal models of cancer. J Nutr 136: 2375 – 2425

Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA (2001) Effect of a high caloric supplement on muscle mass and daily activity in patients with pancreatic cancer cachexia. Nutr Cancer 40: 118 – 124

Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC (1999) The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 81: 80 – 86

Biolo G, De Cicco M, Dal Mas V, Lorenzon S, Antonione R, Ciocchi B, Barazzoni R, Zanetti M, Dore F, Guarnieri G (2006) Response of muscle protein and glutamine kinetics to branched-chain-enriched amino acids in intensive care patients after radical cancer surgery. Nutrition 22: 475 – 482

Brucka E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V (2003) Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 21: 129 – 134

Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E (2004) Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer 101: 370 – 378

Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E (1999) Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res 5: 3942 – 3947

Cangiano C, Laviano A, Meguid MM, Mulieri M, Conversano L, Preziosa I, Rossi-Fanelli F (1996) Effects of administration of oral branched-chain amino acids on anorexia and caloric intake in cancer patients. J Nutr Cancer 88: 550 – 552

Chevalier V, Mormont MC, Cure H, Chollet P (2003) Assessment of circadian rhythms by actimetry in healthy subjects and patients with advanced colorectal cancer. Oncol Rep 10: 733 – 737

Choudry HA, Pan M, Karinch AM, Souba WW (2006) Branched-chain amino acid-enriched nutritional support in surgical and cancer patients. J Nutr 136: 314S – 318S

Colomer R, Moreno-Nogueira JM, Garcia-Luna PP, Garcia-Peiris P, Garcia-de-Lorenzo A, Zaraza A, Quecedo L, Del Llano J, Usan L, Casimiro C (2007) n-3 Fatty acids, cancer and cachexia: a systematic review of the literature. Br J Nutr 97: 823 – 831

Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ (2006) Hypothalamic mTOR signaling regulates food intake. Science 312: 927 – 930
Diffee GM, Kalfas K, Al-Majid S, McCarthy DO (2002) Alternative expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol 283: C1376–C1382

Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Loccisano G, Mantovani G, Marks D, Mitchell WE, Muscaritoli M, Najand A, Ponikowski P, Rossi Fanelli F, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD (2008) Cachexia: A new definition. Clin Nutr 21: 23

Fearon KCH, von Meyenfeldt MF, Moses AGW, Van Gerenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronsen NK, Voss AC, Tisdale MJ (2003) Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52: 1479–1486

Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K, Takaoka Y (2006) Capetcitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse models cachexia cancer models. Cancer Chemother Pharmacol 29: 29

Garcia-de-Lorenzo A, Ortiz-Leyba C, Planas M, Montejo JC, Nunez R, Ordenez FJ, Aragon C, Jimenez FJ (1997) Parenteral administration of different amounts of branch-chain amino acids in septic patients: clinical and metabolic aspects. Crit Care Med 25: 418–424

Gogos CA, Ginopoulos P, Salsa B, Apostolidou E, Zoubous NC, Kalfarentzos F (1998) Dietary omega-3 polysaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer 82: 395–402

Gorselink M, Keizer HA, van Loon LJ (2005) Combined ingestion of protein and free leucine with carbohydrate increases postexercise muscle protein synthesis. J Nutr 135: 2345–2351

Hiroshige K, Sonta T, Suda T, Kanegae K, Ohtani A (2001) Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis. Nephrol Dial Transplant 16: 1856–1862

Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, Gaggin B, Wagenmakers AJ, Manders RJ, Bu, Roy TJ, Nair S, Christiansen B (2004) An eicosapentaenoic acid supplement vs megestrol acetate vs both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22: 2469–2476

Jimenez F, Oriz Leyba C, Morales Menendez S, Barros Perez M, Munoz Garcia JC (1995) Prospective study on the efficacy of branched-chain amino acids in septic patients. JPEN J Parenter Enteral Nutr 19: 252–261

Kalantar-Zadeh K, Kovacev PS, Derose SF, Horwich TB, Fonarow GC (2009) Dietary supplementation with a specific combination of branched chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg 89: 811–815

Mormont MC, Levi F (1997) Circadian-system alterations during cancer processes: a review. Int J Cancer 70: 241–247

Mormont MC, Waterhouse J, Bleuxen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Toutuou Y, Levi F (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6: 3038–3045

Morrow GR, Andrews PL, Hickok JT, Rocca J, Matteson S (2002) Fatigue associated with cancer and its treatment. Support Care Cancer 10: 397–400

Moses AW, Slater C, Preston T, Barber MD, Fearon KC (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90: 996–1002

Muscaritoli M, Bossola M, Bellanotte B, Rossi Fanelli F (2004) Therapy of muscle wasting in cancer: what is the future? Eur J Nutr Metab Care 4: 459–466

Poon RT, Yu WC, Fan ST, Wong J (2004) Long-term oral branched chain amino acids in patients undergoing chemomobilization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 19: 779–788

Rennie MJ, Bohe J, Smith K, Wackerger H, Greenhaff P (2006) Branched-chains amino acids as fuels and anabolic signals in human muscle. J Nutr 136: 2645–2685

Rieu I, Balage M, Sorret C, Giraudet C, Pujos E, Grizard J, Mosconi L, Dardevet D (2006) Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. J Physiol 572: 305–315

Rooyackers OE, Nair KS (1997) Hormonal regulation of human muscle protein metabolism. Am Rev Respir Dis 156: 475–487

Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attix A (2000) Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice. Cancer Res 60: 4968–4974

Surgery 177: 184–191

Weber MA, Kraakowski-Roosen H, Schroder L, Kinscherf R, Krix M, Kopp-Schneider A, Essig M, Bachert P, Kauzour HS, Hildebrandt W (2008) Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol 19: 1–9

Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC (2000) Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 36: 177–182

Wigmore SJ, Ross MJ, Packer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KC (1996) The effect of polysaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 12: 527–530

Zaouali-Ajina M, Gharib A, Durand G, Gazzah N, Claustret B, Gharib C, Sarda N (1999) Dietary docosahexaenoic acid-enriched phospholipids normalize urinary melatonin excretion in adult (n-3) polysaturated fatty-acid-deficient rats. J Nutr 129: 2074–2080